Would Subsidising Weight Loss Drugs Make Health Care Fairer?
How Financial Barriers Shape Treatment Access
GLP-1 medicines like Ozempic, Wegovy and Mounjaro have transformed obesity treatment in Australia, with around half a million people now using them. However, access is increasingly determined by financial means rather than medical need, as nearly half of users pay for these drugs privately, creating a growing divide in who can benefit from these effective treatments.
The high cost of GLP-1 receptor agonists places them out of reach for many Australians, particularly those from lower socioeconomic backgrounds who often experience the highest rates of obesity and related health complications such as type 2 diabetes and cardiovascular disease. While these medications demonstrate significant efficacy in weight reduction and metabolic improvement, their listing on the Pharmaceutical Benefits Scheme remains limited, forcing patients to bear substantial out-of-pocket expenses that can exceed hundreds of dollars per month.
Could Government Subsidies Improve Health Equity?
Private prescriptions for GLP-1 medicines now account for nearly 50% of all usage in Australia, indicating a shift toward a two-tier system where affordability dictates access. Patients with private health insurance or higher incomes are more likely to sustain long-term therapy, while others may discontinue treatment due to cost, despite clinical need. This trend raises concerns about equity in preventive care, especially as obesity disproportionately affects disadvantaged communities. Experts warn that without broader public subsidy, the health benefits of these drugs will remain unevenly distributed, potentially widening existing health disparities.
Subsidising GLP-1 medicines through the Pharmaceutical Benefits Scheme could align access with medical need rather than financial capacity, particularly for individuals with obesity-related comorbidities. Proponents argue that such investment may reduce long-term healthcare costs by preventing diabetes, heart disease, and other obesity-driven conditions. However, questions remain about budget impact, eligibility criteria, and whether subsidies should prioritise those with the greatest clinical burden. Policymakers face the challenge of balancing immediate fiscal pressures with the potential for preventive care to yield future savings and improved population health outcomes.
What percentage of Australians using GLP-1 medicines pay for them privately? Nearly half of the approximately 500,000 Australians using GLP-1 medicines access them through private prescriptions, paying full cost out of pocket.
Frequently Asked Questions
Why are GLP-1 medicines not widely available through public subsidy in Australia? Currently, GLP-1 medicines have limited listings on the Pharmaceutical Benefits Scheme, primarily restricted to specific indications like type 2 diabetes, with broader obesity treatment access requiring private payment.
How might subsidising these drugs affect long-term healthcare costs? While upfront costs would increase, subsidies could reduce future expenses by preventing obesity-related complications such as diabetes, cardiovascular disease, and associated hospitalisations.